LOSTOCK PHARMACHEM LIMITED

Company Registration Number:
13111184 (England and Wales)

Unaudited statutory accounts for the year ended 31 January 2025

(Dormant)

Period of accounts

Start date: 01 February 2024

End date: 31 January 2025

LOSTOCK PHARMACHEM LIMITED

Contents of the Financial Statements

for the Period Ended 31 January 2025

Company Information - 3
Balance sheet - 4
Additional notes - 6
Balance sheet notes - 9

LOSTOCK PHARMACHEM LIMITED

Company Information

for the Period Ended 31 January 2025




Director: Andrew Caunce
Registered office: Lynstock House
Lynstock Way
Bolton
GBR
BL6 4SA
Company Registration Number: 13111184 (England and Wales)

LOSTOCK PHARMACHEM LIMITED

Balance sheet

As at 31 January 2025


Notes

2025
£

2024
£
Fixed assets
Total fixed assets: - -
Current assets
Debtors: 4 100 100
Total current assets: 100 100
Net current assets (liabilities): 100 100
Total assets less current liabilities: 100 100
Creditors: amounts falling due after more than one year: 5 ( 62,645 ) ( 62,645 )
Total net assets (liabilities): ( 62,545 ) ( 62,545 )

The notes form part of these financial statements

LOSTOCK PHARMACHEM LIMITED

Balance sheet continued

As at 31 January 2025


Notes

2025
£

2024
£
Capital and reserves
Called up share capital: 100 100
Profit and loss account: ( 62,645 ) ( 62,645 )
Shareholders funds: ( 62,545 ) ( 62,545 )

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

For the year ending 31 January 2025 the company was entitled to exemption under section 480 of the Companies Act 2006 relating to dormant companies.

This report was approved by the board of directors on 3 October 2025
And Signed On Behalf Of The Board By:

Name: Andrew Caunce
Status: Director

The notes form part of these financial statements

LOSTOCK PHARMACHEM LIMITED

Notes to the Financial Statements

for the Period Ended 31 January 2025

  • 1. Accounting policies

    Basis of measurement and preparation

    These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

LOSTOCK PHARMACHEM LIMITED

Notes to the Financial Statements

for the Period Ended 31 January 2025

  • 2. Employees


    2025

    2024
    Average number of employees during the period 0 0

LOSTOCK PHARMACHEM LIMITED

Notes to the Financial Statements

for the Period Ended 31 January 2025

  • 3. Off balance sheet disclosure

    No

LOSTOCK PHARMACHEM LIMITED

Notes to the Financial Statements

for the Period Ended 31 January 2025

4. Debtors


2025
£

2024
£
Other debtors 100 100
Total 100 100

LOSTOCK PHARMACHEM LIMITED

Notes to the Financial Statements

for the Period Ended 31 January 2025

5.Creditors: amounts falling due after more than one year


2025
£

2024
£
Other creditors 62,645 62,645
Total 62,645 62,645